Lilly sues to block copy of Evista osteoporosis drug

  • Comments
  • Print
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
This audio file is brought to you by
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Eli Lilly and Co. sued Watson Pharmaceuticals Inc. to prevent the sale of a generic version of its osteoporosis drug Evista
in the United States.

Watson, based in Corona, Calif., filed for U.S. Food and Drug Administration approval to sell a low-cost version of the Lilly
medicine, which contains the active ingredient raloxifene hydrochloride. Indianapolis-based Lilly is seeking a court order
that would block approval until three of its patents expire in 2017.

Evista is a bone-loss treatment first approved by regulators in 1997 and used to treat women after menopause. A study released
last month indicated that raloxifene also may provide some protection against breast cancer in women. The drug generated $682.2
million in U.S. sales last year for Lilly, the company said Jan. 28.

In its FDA application, Watson contends the patents are invalid, unenforceable or not infringed, according to a complaint
filed by Lilly on May 3 in federal court in Indianapolis.

Please enable JavaScript to view this content.

Story Continues Below

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news. ONLY $1/week Subscribe Now

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Get the best of Indiana business news.

Limited-time introductory offer for new subscribers

ONLY $1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In